


**Amendments To The Claims**

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

**Listing of Claims:**

1. (Currently **Amended**) A compound of the following Formula I:



wherein

A is hydrogen or hydroxy;

B is selected from optionally substituted carbocyclic aryl and optionally substituted heteroalicyclic having from 3 to 8 ring atoms and at least 1 N, O or S ring atom or a heteroaromatic group having a single ring with 5 or 6 ring atoms and at least one N, O or S ring atom;

U is  $(CH_2)_p$  wherein p is selected from 0, 1 and 2;

V and Q are each independently hydrogen, ~~optionally~~ substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,  $C_1$ - $C_6$  heteroalkyl,  $C_3$ - $C_6$  cycloalkyl  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  heterocycloalkyl  $C_1$ - $C_6$  alkyl, arylalkyl,  $-CR^1R^2-W$ , wherein  $R^1$  and

$R^2$  are independently selected from H, propyl, pentyl, substituted ~~and~~  $C_1$ - $C_6$  alkyl; or  $R^1$  and  $R^2$  can form a  $C_3$ - $C_6$  cycloalkyl with the carbon they are attached to;


W is selected from hydrogen,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_3$ - $C_6$  cycloalkyl  $C_1$ - $C_6$  alkyl, aryl and heteroaryl; with at least one of V and Q being other than hydrogen; and pharmaceutically acceptable salts thereof.

2. (**Original**) A compound of claim 1 wherein A is hydrogen.

3. (**Previously Presented**) A compound of claim 1 wherein B is optionally substituted carbocyclic aryl.

4. **(Previously Presented)** A compound of claim 1 wherein B is optionally substituted phenyl.

5. **(Currently Amended)** A compound of ~~claim 1 having the following~~ Formula II:



II

wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

X is selected from oxygen, sulfur, sulfinyl, sulfonyl and carbon;

n is an integer selected from 0, 1, 2, 3, 4 and 5;


U is (CH<sub>2</sub>)<sub>p</sub> wherein p is selected from 0, 1 and 2;

V and Q are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> heterocycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, arylalkyl and -CR<sup>1</sup>R<sup>2</sup>-W, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>1</sup> and R<sup>2</sup> can form an C<sub>3</sub>-C<sub>6</sub> cycloalkyl with the carbon they are attached to;

W is selected from hydrogen, propyl, pentyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl and heteroaryl; with at least one of V and Q being other than hydrogen; and pharmaceutically acceptable salts thereof.

6. **(Original)** A compound of claim 5 wherein n is 1 or 2.

7. **(Currently Amended)** A compound of claim 1 having the following Formula III:



III


wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

U is (CH<sub>2</sub>)<sub>p</sub> wherein p is selected from 0, 1 and 2;

V and Q are each independently selected from hydrogen, ~~optionally~~ substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> heterocycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, arylalkyl and -CR<sup>1</sup>R<sup>2</sup>-W, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>1</sup> and R<sup>2</sup> can form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl with the carbon they are attached to;

W is selected from hydrogen, propyl, pentyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl and heteroaryl; with at least one of V and Q being other than hydrogen; and pharmaceutically acceptable salts thereof.

8. **(Currently Amended)** A compound of claim 1 having the following Formula IV:



IV

wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;


n is an integer selected from 0, 1, 2, 3, 4 and 5;

U is (CH<sub>2</sub>)<sub>p</sub> wherein p is selected from 0, 1 and 2;

Q is ~~optionally~~ substituted ~~from~~ alkyl, preferably having 1 to about 12 carbon atoms, optionally substituted alkenyl preferably having 2 to about 12 carbon atoms, optionally substituted alkynyl preferably having from 2 to about 12 carbon atoms, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> heterocycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl C<sub>1</sub>-C<sub>6</sub> alkyl and -CR<sup>1</sup>R<sup>2</sup>-W, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>1</sup> and R<sup>2</sup> can form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl with the carbon they are attached to;

W is selected from hydrogen, propyl, pentyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl and aryl C<sub>1</sub>-C<sub>6</sub> alkyl; and pharmaceutically acceptable salts thereof.

9. **(Previously Presented)** A compound of claim 1 wherein p is zero.
10. **(Currently Amended)** A compound of claim 1 having the following Formula V:



V

wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

n is an integer selected from 0, 1, 2, 3, 4 and 5;

Q is selected from ~~optionally~~ substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted arylalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> heterocycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl C<sub>1</sub>-C<sub>6</sub> alkyl and -CR<sup>1</sup>R<sup>2</sup>-W, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>1</sup> and R<sup>2</sup> can form an C<sub>3</sub>-C<sub>6</sub> cycloalkyl with the carbon they are attached to;

W is selected from hydrogen, propyl, pentyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl and aryl C<sub>1</sub>-C<sub>6</sub> alkyl; and pharmaceutically acceptable salts thereof.

11. **(Original)** A compound of claim 10 wherein n is 1 and R is a *para*-substituent.
12. **(Original)** A compound of claim 10 wherein R is -C(O)OH.
13. **(Currently Amended)** A compound of claim 10 wherein Q is ~~straight or~~ branched C<sub>1</sub>-C<sub>12</sub> alkyl or optionally substituted arylalkyl.
14. **(Currently Amended)** A compound of claim 10 wherein R is -C(O)OH being in a "para" position whereby n is 1; Q is CR<sup>1</sup>R<sup>2</sup>-W, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>1</sup> and R<sup>2</sup> can form an C<sub>3</sub>-C<sub>6</sub> cycloalkyl with the carbon they are attached to; W is selected from hydrogen, propyl, pentyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl and aryl C<sub>1</sub>-C<sub>6</sub> alkyl; and pharmaceutically acceptable salts thereof.

15. **(Currently Amended)** A compound of claim 10 wherein R is -C(O)OH is in a "para" position; n is 1; Q is CR<sup>1</sup>R<sup>2</sup>-W, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>1</sup> and R<sup>2</sup> can form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl with the carbon they are attached to; W is selected from hydrogen, propyl, pentyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, and aryl; and pharmaceutically acceptable salts thereof.

16. **(Currently Amended)** A compound of claim 1 that is selected from the group consisting of:

4-(2-((2R)-2-[(1E,4S)-4-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,4R)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-[2-((2R)-2-[(1E,4R)-4-[1-(cyclopropylmethyl)cyclobutyl]-4-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
4-(2-((2R)-2-[(1E,4R)-4-(1-ethylcyclobutyl)-4-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2S)-2-[(1E,4S)-4-hydroxy-4-ethyloct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
-(2-((2S)-2-[(1E,4S)-4-hydroxy-4-ethyloct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
~~4-(2-((2R)-2-[(1E,3S)-3-hydroxyoct-1-en-7-ynyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;~~  
4-(2-((2R)-2-[(1E,3S)-3-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzamide;  
4-(2-((2R)-2-[(1E,3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3R)-4-(allyloxy)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3R,7S)-3,7-dihydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid  
4-(2-((2R)-2-[(1E,3S,7S)-3,7-dihydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3R,7R)-3,7-dihydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E)-3-hydroxy-5-morpholin-4-ylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxyhepta-1,6-dienyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-4-cyclopropyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3R)-4-cyclopentyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-4-cyclopentyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3R)-4-cyclopropyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-6-methylhept-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-5-methylhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-5,5-dimethylhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-6-cyclopropyl-3-hydroxyhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3R)-3-hydroxy-5-methoxypent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-5-methoxypent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((5R)-2-oxo-5-[(1E,3S)-6,6,6-trifluoro-3-hydroxyhex-1-enyl]pyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-4-cyclohexyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxypent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxyhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-6-methoxyhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S,7R)-3,7-dihydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3R)-4-(4-chlorophenyl)-3-hydroxy-4-methylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-[2-((2R)-2-((1E,3S)-3-[1-(cyclopropylmethyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-[2-((2R)-2-((1E,3R)-3-[1-(cyclopropylmethyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-(2-((2S)-2-[(3S)-3-(1-butylcyclobutyl)-3-hydroxypropyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2S)-2-[(3R)-3-(1-butylcyclobutyl)-3-hydroxypropyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3R)-3-hydroxy-3-(1-phenylcyclopentyl)prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-3-(1-phenylcyclopentyl)prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-[2-((2R)-2-((1E,3R)-3-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-[2-((2R)-2-((1E,3S)-3-[1-(4-chlorophenyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-[2-((2R)-2-((1E,3R)-3-[1-(4-chlorophenyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-[2-((2R)-2-((1E,3S)-3-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-[2-((2R)-2-((1E,3S)-3-hydroxy-3-[1-(4-methylphenyl)cyclopentyl]prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-[2-((2R)-2-((1E,3R)-3-hydroxy-3-[1-(4-methylphenyl)cyclopentyl]prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-(2-((2R)-2-[(1E,3S)-4-(4-chlorophenyl)-3-hydroxy-4-methylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-[2-((2R)-2-((1E,3S)-3-[1-(4-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-[2-((2R)-2-((1E,3R)-3-[1-(4-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-[2-((2R)-2-((1E,3R)-3-[1-(2-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl)-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
4-[2-((2R)-2-((1E,3S)-3-[1-(2-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl)-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
4-[2-((2R)-2-((1E,3S)-3-[1-(4-chlorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl)-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
4-[2-((2R)-2-((1E,3R)-3-[1-(4-chlorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl)-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-4-(3-methylphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxyhept-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-4-(3-chlorophenyl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2S)-2-[(3R)-3-hydroxy-4-methyl-4-phenylpentyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-4-methyl-4-phenylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3R)-3-hydroxy-4-methyl-4-phenylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2S)-2-[(3S)-3-hydroxynonyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-[2-((2R)-2-((1E,3S)-3-[1-(3-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl)-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
4-[2-((2R)-2-((1E,3R)-3-[1-(3-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl)-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxynon-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-[2-((2R)-2-((1E,3S)-3-hydroxy-3-[1-(2-phenylethyl)cyclobutyl]prop-1-enyl)-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
4-[2-((2R)-2-((1E,3R)-3-hydroxy-3-[1-(2-phenylethyl)cyclobutyl]prop-1-enyl)-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-3-(1-propylcyclobutyl)prop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid  
4-(2-((2R)-2-[(1E,3R)-3-hydroxy-3-(1-propylcyclobutyl)prop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid  
4-(2-((2R)-2-[(1E,3R)-3-(1-benzylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E)-3-hydroxy-3-methyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E)-4-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3R)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3R)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-7-methyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-5-cyclopentyl-3-hydroxypent-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid; and pharmaceutically acceptable salts thereof.

Claim 17. **(Cancelled).**

18. **(Previously Presented)** A method for treating a disease or disorder associated with prostaglandin, comprising administering to a mammal suffering from or susceptible to such a disease or disorder an effective amount of a compound of claim 1.

19. **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to asthma.

20.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to hypertension.
21.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to undesired blood clotting.
22.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to infertility or a fertility disorder.
23.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to an eosinophil disorder.
24.     **(Original)** A method of claim 18 wherein the mammal is suffering from sexual dysfunction.
25.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to glaucoma or other disorder involving elevated intraocular pressure.
26.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to renal dysfunction.
27.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to an immune deficiency disease or disorder.
28.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to AIDS.
29.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to undesired bone loss.
30.     **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to preterm labor.


31. **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to dysmenorrhea.
32. **(Original)** A method of claim 18 wherein the mammal is a female in late stage pregnancy and in need of control of cervical ripening.
33. **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to preelampsia or eclampsia.
34. **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to ichthyosis.
35. **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to dry eye.
36. **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to a sleep disorder.
37. **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to gastric ulcers.
38. **(Original)** A method of claim 18 wherein the mammal is suffering or susceptible to undesired muscle contraction.
39. **(Original)** A method of claim 18 wherein the mammal is suffering or susceptible to inflammatory disorders.
40. **(Original)** A method of claim 18 wherein the mammal is suffering from or susceptible to erectile dysfunction.
41. **(Previously Presented)** A method of claim 18 wherein the mammal is a human.
42. **(Previously Presented)** A method of claim 18 wherein the mammal is a female.

43. **(Original)** A method of claim 42 wherein the female is suffering from or susceptible to infertility.
44. **(Original)** A method of claim 42 wherein the female is suffering from an ovulatory disorder.
45. **(Previously Presented)** A method of claim 18 wherein the mammal is a male.
46. **(Previously Presented)** A method for treating a mammal suffering from or susceptible to preterm labor, dysmenorrhea, asthma, hypertension, a fertility disorder, undesired blood clotting, preeclampsia, eclampsia, an eosinophil disorder, undesired bone loss, sexual dysfunction, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, a sleep disorder, or a gastric ulcer, inflammatory disorder, comprising administering to the mammal an effective amount of a compound of claim 1.


Claims 47-48 **(Cancelled)**.

49. **(Previously Presented)** A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of claim 1.
50. **(Previously Presented)** A pharmaceutical composition of claim 49 wherein the compound is packaged together with instructions for use of the compound to treat preterm labor, dysmenorrhea, asthma, hypertension, infertility or a fertility disorder, sexual dysfunction, undesired blood clotting, a destructive bone disease or disorder, preeclampsia or eclampsia, an eosinophil disorder, renal dysfunction an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer.
51. **(Currently Amended)** A method of treating a fertility condition in a female, comprising the administration to said female a prostaglandin EP4 receptor agonist, ~~a pro-drug thereof~~ or a pharmaceutical acceptable salt of said compound, ~~pro-drug or a~~ diastereoisomeric mixture of said compound, or salt or pro-drug.

52. **(Original)** A method of claim 51 wherein the condition is infertility.
53. **(Original)** A method of claim 51 wherein the condition is an ovulatory disorder.
54. **(Previously Presented)** A method of claim 51 wherein the female is undergoing an ovulation induction or ART treatments.
55. **(Currently Amended)** A method of claim 51 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI:



VI



wherein A is H or OH, preferably H;

B is selected from C<sub>1</sub>-C<sub>6</sub> alkyl, aryl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl C<sub>1</sub>-C<sub>6</sub> heteroalkyl, heteroaryl C<sub>1</sub>-C<sub>6</sub> alkoxy, aryl, heteroaryl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl and C<sub>3</sub>-C<sub>6</sub> heterocycloalkyl, provided that when B is aryl, heteroaryl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl and C<sub>3</sub>-C<sub>6</sub> heterocycloalkyl, the undefined bond linking B is a single bond;

The dotted line indicates an optional double bond;

R is C(=O)Z wherein Z is selected from hydrogen, hydroxy, alkoxy, alkyl and aryl; or Z is selected from amino or alkylamine such as -NR<sup>1</sup>R<sup>2</sup> wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen and alkyl, -NHSO<sub>2</sub>R<sup>3</sup> and -NHC(O)R<sup>3</sup> wherein R<sup>3</sup> is selected among C<sub>1</sub>-C<sub>6</sub> alkyl and aryl; or R is heteroaryl;

U is  $(CH_2)_p$  wherein p is an integer selected from 0, 1 and 2;

Q is  $-CR^4R^5-W$ , wherein  $R^4$  and  $R^5$  are independently selected from H, halogen and  $C_1-C_6$  alkyl; or  $R^4$  and  $R^5$  can form a  $C_3-C_6$  cycloalkyl with the carbon they are attached to;

W is selected from hydrogen,  $C_1-C_6$  alkyl,  $C_3-C_6$  cycloalkyl,  $C_3-C_6$  heterocycloalkyl,  $C_3-C_6$  cycloalkyl  $C_1-C_6$  alkyl,  $C_3-C_6$  heterocycloalkyl  $C_1-C_6$  alkyl, aryl, heteroaryl, aryl  $C_1-C_6$  alkyl and heteroaryl  $C_1-C_6$  alkyl; and pharmaceutically acceptable salts thereof.

56. **(Original)** A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI, wherein A is H; B is  $C_1-C_6$  alkyl whereby B is linked by a single bond; R is  $C(=O)Z$  wherein Z is selected from hydrogen, hydroxy, alkoxy such as  $-O$ -alkyl and alkyl; or Z is selected from amino or alkylamine such as  $-NR^1R^2$  where  $R^1$  and  $R^2$  are independently hydrogen or alkyl,  $-NHSO_2R^3$  and  $-NHC(O)R^3$  wherein  $R^3$  is selected among  $C_1-C_6$  alkyl and aryl; U is  $(CH_2)_p$  wherein p is 0; Q is  $-CR^4R^5-W$ , wherein  $R^4$  and  $R^5$  are independently selected from H, halogen and  $C_1-C_6$  alkyl; W is selected from  $C_3-C_6$  cycloalkyl,  $C_3-C_6$  heterocycloalkyl, optionally substituted aryl and heteroaryl; and pharmaceutically acceptable salts thereof.

57. **(Original)** A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI, wherein A is H; B is  $C_1-C_6$  alkyl; R is  $C(=O)Z$  wherein Z is selected from hydrogen, hydroxy, alkoxy; or R is heteroaryl; U is  $(CH_2)_p$  wherein p is 0; Q is  $-CH_2-W$ , wherein W is selected from  $C_3-C_6$  cycloalkyl,  $C_3-C_6$  heterocycloalkyl, aryl and heteroaryl; and pharmaceutically acceptable salts thereof.

58. **(Original)** A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI, wherein A is H; B is selected from aryl  $C_1-C_6$  alkoxy,  $-CH_2$ -aryl and  $-CH_2$ -heteroaryl whereby B is linked by a single bond; R is  $C(=O)Z$  wherein Z is selected hydrogen, hydroxy and alkoxy; or R is heteroaryl; U is  $(CH_2)_p$  wherein p is 0; Q is  $-CH_2-W$ , wherein W is selected from  $C_3-C_6$  cycloalkyl,  $C_3-C_6$  heterocycloalkyl, aryl and heteroaryl; and pharmaceutically acceptable salts thereof.

59. **(Currently Amended)** A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI wherein A is H; B is

substituted aryl whereby B is linked by a single bond; R is C(=O)Z wherein Z is hydroxy; U is (CH<sub>2</sub>)<sub>p</sub> wherein p is 0; Q is -CR<sup>4</sup>R<sup>5</sup>-W, wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>4</sup> and R<sup>5</sup> can form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl with the carbon they are attached to; W is selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl and substituted phenyl; and pharmaceutically acceptable salts thereof.

60. **(Currently Amended)** A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected from the group consisting of:

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-4-(3-chlorophenyl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3R)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-6-cyclopropyl-3-hydroxyhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxyhepta-1,6-dienyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxy-6-methylhept-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-[2-((2R)-2-[(1E,3R)-3-[1-(cyclopropylmethyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;  
~~4-(2-((2R)-2-[(1E,3S)-3-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;~~  
4-(2-((2R)-2-[(1E,3R)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2R)-2-[(1E,3S)-3-hydroxynon-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
4-(2-((2S)-2-[(3R)-3-hydroxy-4-(3-methylphenyl)butyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2S)-2-[(3R)-3-hydroxy-5-phenylpentyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;  
and pharmaceutically acceptable salts thereof.

61. (New) A method for treating a disease or disorder associated with prostaglandin, comprising administering to a mammal suffering from or susceptible to such a disease or disorder an effective amount of a compound of claim 5.

62. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to asthma.

63. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to hypertension.

64. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to undesired blood clotting.

65. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to infertility or a fertility disorder.

66. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to an eosinophil disorder.

67. (New) A method of claim 61 wherein the mammal is suffering from sexual dysfunction.

68. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to glaucoma or other disorder involving elevated intraocular pressure.


69. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to renal dysfunction.

70. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to an immune deficiency disease or disorder.

71. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to AIDS.
72. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to undesired bone loss.
73. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to preterm labor.
74. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to dysmenorrhea.
75. (New) A method of claim 61 wherein the mammal is a female in late stage pregnancy and in need of control of cervical ripening.
76. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to preeclampsia or eclampsia.
77. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to ichthyosis.
78. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to dry eye.
79. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to a sleep disorder.
80. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to gastric ulcers.
81. (New) A method of claim 61 wherein the mammal is suffering or susceptible to undesired muscle contraction.

82. (New) A method of claim 61 wherein the mammal is suffering or susceptible to inflammatory disorders.
83. (New) A method of claim 61 wherein the mammal is suffering from or susceptible to erectile dysfunction.
84. (New) A method of claim 61 wherein the mammal is a human.
85. (New) A method of claim 61 wherein the mammal is a female.
86. (New) A method of claim 85 wherein the female is suffering from or susceptible to infertility.
87. (New) A method of claim 85 wherein the female is suffering from an ovulatory disorder.
88. (New) A method of claim 61 wherein the mammal is a male.
89. (New) A method for treating a mammal suffering from or susceptible to preterm labor, dysmenorrhea, asthma, hypertension, a fertility disorder, undesired blood clotting, preclampsia, eclampsia, an eosinophil disorder, undesired bone loss, sexual dysfunction, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, a sleep disorder, a gastric ulcer, or an inflammatory disorder, comprising administering to the mammal an effective amount of a compound of claim 5.
90. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of claim 5.
91. (New) A pharmaceutical composition of claim 90 wherein the compound is packaged together with instructions for use of the compound to treat preterm labor, dysmenorrhea, asthma, hypertension, infertility or a fertility disorder, sexual dysfunction, undesired blood clotting, a destructive bone disease or disorder, preeclampsia or eclampsia, an eosinophil disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer.

92. (New) A method for treating a mammal suffering from or susceptible to preterm labor, dysmenorrhea, a fertility disorder, undesired blood clotting, preeclampsia, eclampsia, an eosinophil disorder, undesired bone loss, sexual dysfunction, dry eye, ichthyosis, a sleep disorder, or a gastric ulcer, comprising administering to the mammal an effective amount of a compound of Formula (I):



I

wherein

A is hydrogen or hydroxy;


B is selected from optionally substituted carbocyclic aryl and optionally substituted heteroalicyclic having from 3 to 8 ring atoms and at least 1 N, O or S ring atom or a heteroaromatic group having a single ring with 5 or 6 ring atoms and at least one N, O or S ring atom;

U is  $(CH_2)_p$  wherein p is selected from 0, 1 and 2;

V and Q are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,  $C_1$ - $C_6$  heteroalkyl,  $C_3$ - $C_6$  cycloalkyl  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  heterocycloalkyl  $C_1$ - $C_6$  alkyl, arylalkyl,  $-CR^1R^2-W$ , wherein  $R^1$  and  $R^2$  are independently selected from H and  $C_1$ - $C_6$  alkyl; or  $R^1$  and  $R^2$  can form an  $C_3$ - $C_6$  cycloalkyl with the carbon they are attached to;

W is selected from hydrogen,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_3$ - $C_6$  cycloalkyl  $C_1$ - $C_6$  alkyl, aryl and heteroaryl; with at least one of V and Q being other than hydrogen; and pharmaceutically acceptable salts thereof.

93. (New) A method for treating a mammal suffering from or susceptible to preterm labor, dysmenorrhea, a fertility disorder, undesired blood clotting, preclampsia, eclampsia, an eosinophil disorder, undesired bone loss, sexual dysfunction, dry eye, ichthyosis, a sleep disorder, or a gastric ulcer, comprising administering to the mammal an effective amount of a compound of Formula (II):



II

wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

X is selected from oxygen, sulfur, sulfinyl, sulfonyl and carbon;

n is an integer selected from 0, 1, 2, 3, 4 and 5;

U is (CH<sub>2</sub>)<sub>p</sub> wherein p is selected from 0, 1 and 2;

V and Q are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> heterocycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, arylalkyl and -CR<sup>1</sup>R<sup>2</sup>-W, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl; or R<sup>1</sup> and R<sup>2</sup> can form an C<sub>3</sub>-C<sub>6</sub> cycloalkyl with the carbon they are attached to;

W is selected from hydrogen, propyl, pentyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl, aryl and heteroaryl; with at least one of V and Q being other than hydrogen; and pharmaceutically acceptable salts thereof.